Mantle Cell Lymphoma

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

Ruby Arora, MD, discusses findings from a SEER database analysis of mantle cell lymphoma incidence rates from 2000 to 2021.

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Alexey Danilov, MD, PhD, shares key developments and areas of debate from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

R2 followed by R-DHAP led to an ORR of 93.3% in patients with newly diagnosed MCL.

Acalabrutinib plus BR prolonged duration of MRD negativity vs BR alone in previously untreated MCL, supporting the use of MRD as a prognostic biomarker.

Ibrutinib plus venetoclax led to complete responses and durable remissions in the first-line treatment of older patients with MCL.

CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.

Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

Findings from a matching-adjusted indirect comparison showed a PFS benefit with zanubrutinib vs orelabrutinib in relapsed/refractory mantle cell lymphoma.

Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.